Yuichi Tasaka

Yuichi Tasaka

Auto-generated profile, based on publicly available information

Yuichi Tasaka

Laboratory of Clinical Pharmacy, School of Pharmacy, Shujitsu University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
YTYuichi Tasaka
Yuichi Tasaka
ATAkihiro Tanaka
Akihiro Tanaka
DYDaiki Yasunaga
Daiki Yasunaga
TATakashige Asakawa
Takashige Asakawa
HAHiroaki Araki
Hiroaki Araki
MTMamoru Tanaka
Mamoru Tanaka
Pharmaceutical intervention enables safe and effective pharmacotherapy by avoiding of adverse drug reactions (ADRs) and efficacy attenuations. Many prescriptions require optimization, and pharmaceutical interventions are inextricably associated with the prevention of potential drug-related problems (DRPs). Although the analysis and understanding of pharmaceutical interventions can lead to improvement in prescription, the analysis of routine pharmaceutical interventions in Japan in insufficient. Thus, we conducted this study to understand potential DRPs by analyzing routine pharmaceutical interventions made by pharmacists in Japan. Pharmacists register the details of pharmaceutical interventions (excluding personal patient information) in a web-based database. We classified data of pharmaceutical interventions into 13 DRP types, 43 DRP subtypes, and 10 intervention categories (e.g., avoidance of serious ADRs and renal dosing recommendations). These data were analyzed with a focus on renal dysfunction and polypharmacy. During the study period, 2376 pharmaceutical interventions were performed. Overall, 68.2% of pharmaceutical interventions were for patients aged over 65 years. The most frequently detected potential DRP was overdosage, followed by omission of prescription, contraindications, and duplication of a drug with similar effect. The main cause of contraindication and overdosage was renal function deterioration, and that of polypharmacy was duplication of a drug with similar effect. Using our original evidence-based approach, we found that 2376 pharmaceutical interventions prevented ADRs for 1678 drugs, with potential cost savings of up to USD 2,657,820. Our results indicate that the analysis of routine pharmaceutical interventions is beneficial for detecting potential DRPs. Our findings also show that, in an aging society, pharmacists have an important role in providing medication safety, with potential cost savings.

8 January 2016 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
YTYuichi Tasaka
Yuichi Tasaka
DYDaiki Yasunaga
Daiki Yasunaga
MTMamoru Tanaka
Mamoru Tanaka
ATAkihiro Tanaka
Akihiro Tanaka
TATakashige Asakawa
Takashige Asakawa
HAHiroaki Araki
Hiroaki Araki

1 March 2015 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
YTYuichi Tasaka
Yuichi Tasaka
DYDaiki Yasunaga
Daiki Yasunaga
TKTakeshi Kiyoi
Takeshi Kiyoi
MTMamoru Tanaka
Mamoru Tanaka
ATAkihiro Tanaka
Akihiro Tanaka
HAHiroaki Araki
Hiroaki Araki
Ulcerative colitis (UC) involves chronic inflammation of the large intestine. Several agents are used to treat UC, but adverse side effects are remaining problems. We examined the effect of tropisetron as a new type of drug for UC using a dextran sulfate sodium (DSS)-induced model of colitis in mice. We developed a DSS-induced model of colitis and calculated the Disease Activity Index and colon length. We measured myeloperoxidase activity and determined the protein level and mRNA level of cytokines in the colon. DSS-induced colitis was ameliorated by administration of tropisetron and PNU282987. Pre-administration of methyllycaconitine diminished the suppressive effect of tropisetron upon DSS-induced colitis. These findings suggested that α7 nicotinic acetylcholine receptors (α7 nAChRs) were related to the suppressive effect of tropisetron on DSS-induced colitis. Additionally, stimulation of α7 nAChRs decreased the colon level of interleukin-6 and interferon-γ upon DSS administration. Furthermore, stimulation of α7 nAChRs decreased macrophage infiltration, with expression of α7 nAChR increased by DSS administration. These results suggest that the underlying mechanism of this suppressive effect on DSS-induced colitis is via stimulation of α7 nAChRs and involves suppression of expression of pro-inflammatory cytokines. Tropisetron could be a new type of therapeutic agent for UC.

20 September 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
YIYasuhisa Izushi
Yasuhisa Izushi
STShouki Tanaka
Shouki Tanaka
TUTeppei Ueda
Teppei Ueda
SUSoichiro Ushio
Soichiro Ushio
YTYuichi Tasaka
Yuichi Tasaka
YKYoshihisa KITAMURA
Yoshihisa KITAMURA

5 August 2024 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
RMRina Matsuoka
Rina Matsuoka
SAShinsuke Akagi
Shinsuke Akagi
TKTomohiro Konishi
Tomohiro Konishi
MKMasashi Kondo
Masashi Kondo
HMHideki Matsubara
Hideki Matsubara
YTYuichi Tasaka
Yuichi Tasaka
Background: Drug-drug interactions (DDIs) increase the incidence of adverse drug reactions (ADRs). In a previous report, we revealed that the incidence of potential DDIs due to the same CYP molecular species in one prescription exceeds 90% among patients taking six or more drugs and that CYP3A4 markedly influences the increase in the number of potential DDIs in clinical practice. However, the factors contributing to an increased number of potential DDIs in prescriptions from multiple clinical departments remain poorly clarified. Methods: This observational study was performed at five pharmacies in Okayama Prefecture, Japan. Patients who visited these pharmacies from 11 April 2022 to 24 April 2022 were included, except those who had prescriptions only from a single clinical department. A stratified analysis was performed to determine the incidence of CYP3A4-related potential DDIs according to the number of drugs taken. Additionally, factors associated with an increase in the number of drugs involved in CYP3A4-related potential DDIs were identified using multiple linear regression analysis. In this study, potential DDIs for the prescription data subdivided by clinical department, containing two or more drugs, were used as control data. Results: Overall, 372 outpatients who received prescriptions from multiple clinical departments were included in the current study. The number of drugs contributing to CYP3A4-related potential DDIs increased with an increase in the number of clinical departments. Notably, in cases taking fewer than six drugs, prescriptions from multiple clinical departments had a higher frequency of CYP3A4-related potential DDIs than those in prescriptions subdivided by clinical department. Multiple regression analysis identified "Cardiovascular agents", "Agents affecting central nervous system", and "Urogenital and anal organ agents" as the top three drug classes that increase CYP3A4-related potential DDIs. Conclusion: Collectively, these results highlight the importance of a unified management strategy for prescribed drugs and continuous monitoring of ADRs in outpatients receiving prescriptions from multiple clinical departments even if the number of drugs taken is less than six.

1 July 2021 in YAKUGAKU ZASSHI
Verified
Journal Article
Closed access
PDF file
NONatsumi Oka
Natsumi Oka
MKMasashi Kondo
Masashi Kondo
HMHideki Matsubara
Hideki Matsubara
KIKeiji Izushi
Keiji Izushi
YTYuichi Tasaka
Yuichi Tasaka
Drug-drug interactions (DDIs) are responsible for an increase in the incidence of adverse drug reactions. Although CYP is known to be involved in metabolic processes, the DDIs among three or more drugs that involve the same CYP molecular species have not been fully investigated. In this study, we retrospectively examined the relationship between the number of drugs and potential DDIs in metabolic processes involving CYPs in patients who picked up their prescribed drugs at 11 pharmacies in the Kojima Branch of the Okayama Pharmaceutical Association. We found that 66.5% of the 924 patients had potential DDIs; more than half of the patients who took six or more drugs had potential DDIs among three or more drugs. The mean number of CYP3A4-related drugs involved in potential DDIs was 3.52±1.56 in patients who took seven drugs, suggesting the need for careful monitoring of specific symptoms and blood test results for the early detection of adverse drug reactions caused by DDIs among three or more drugs.